AUG 7, 2026 · JOURNAL ARTICLE
CRISPR screens reveal MCT1-driven metabolic escape from SMAD3 inhibition as a therapeutic vulnerability
Molecular Cancer
Well-designed mechanistic study with CRISPR screens and in vivo validation identifies MCT1 as a resistance mechanism to SMAD3 inhibition and demonstrates synergy in preclinical models, but lacks clinical evidence and human efficacy data.
Study details
DesignPreclinical mechanistic study using genome-…
InterventionSMAD3 inhibition combined with pharmacologi…
ComparatorSMAD3 inhibition alone; MCT1 inhibition alo…